Product Images Xeomin

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 15 images provide visual information about the product associated with Xeomin NDC 46783-160 by Merz North America, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Figure 1 - xeomin 01

Figure 1 - xeomin 01

The text provides the names of two glands present in the human body - Parotid gland and Submandibular gland. The Parotid gland is the largest of the salivary glands and is located near the ear. The Submandibular gland is a salivary gland situated underneath the lower jaw.*

Figure 2 - xeomin 02

Figure 2 - xeomin 02

Figure 3 - xeomin 03

Figure 3 - xeomin 03

This appears to be a list of arm muscles, including the biceps brachii, brachioradialis, pronator teres, flexor digitorum profundus, flexor carpl radialis, flexor carpi ulnaris, opponens pollicis, fleor polici longus, flexor pollicis brevis, and addcor pollics.*

Figure 4 - xeomin 04

Figure 4 - xeomin 04

This appears to be a list of muscles and tendons in the forearm and hand, including the biceps brachii, pronator quadratus, flexor muscles (carpi ulnaris, pollicis, digitorum superficialis, and pollicis longus), opponens pollicis, adductor pollicis, and distal tendons of the flexor digitorum profundus. The note at the end suggests that some muscle bellies are not visible.*

Figure 5 - xeomin 05

Figure 5 - xeomin 05

Figure 6 - xeomin 06

Figure 6 - xeomin 06

This text appears to be describing different parts of the orbicularis oculi muscle, including the laceral and medial superior pre-tarsal part, the laceral canthus, and the inferolaceral portion. It also mentions the corrugator muscle. It is likely information pertaining to anatomy or medical study.*

PRINCIPAL DISPLAY PANEL - 50 units/vial Label - xeomin 07

PRINCIPAL DISPLAY PANEL - 50 units/vial Label - xeomin 07

PRINCIPAL DISPLAY PANEL - - 50 units/vial Carton - xeomin 08

PRINCIPAL DISPLAY PANEL - - 50 units/vial Carton - xeomin 08

PRINCIPAL DISPLAY PANEL - 100 units/vial Label - xeomin 09

PRINCIPAL DISPLAY PANEL - 100 units/vial Label - xeomin 09

The text provides a table that shows the "Cumulative Percentage of Patients" and "Change from Baseline on the TWSTRS" for three treatment groups. The treatment groups are not specified with clear headings, but it seems that they are XEOMIN (120 U), XEOMIN (240 U), and Placebo. The numbers in the table refer to the change in TWSTRS for each group, and the cumulative percentage of patients who fall into each category. It is not clear what TWSTRS stands for or what the numbers mean.*

PRINCIPAL DISPLAY PANEL - 100 units/vial Carton - xeomin 10

PRINCIPAL DISPLAY PANEL - 100 units/vial Carton - xeomin 10

The text corresponds to a graph that shows the percentage of patients who experienced a change in JRS after being treated with XEOMIN 50 U, XEOMIN 25 U, or Placebo. There is no additional information available.*

PRINCIPAL DISPLAY PANEL - 100 units/vial Label - Physician Sample - xeomin 11

PRINCIPAL DISPLAY PANEL - 100 units/vial Label - Physician Sample - xeomin 11

PRINCIPAL DISPLAY PANEL - 100 units/vial Carton - Physician Sample - xeomin 12

PRINCIPAL DISPLAY PANEL - 100 units/vial Carton - Physician Sample - xeomin 12

PRINCIPAL DISPLAY PANEL - 50 units/vial Label - Physician Sample - xeomin 13

PRINCIPAL DISPLAY PANEL - 50 units/vial Label - Physician Sample - xeomin 13

This is a product description of a medication called "incobotulinumtoxinA" used for intramuscular injection. The medication is manufactured in Germany by Mz Pharmaceuticals GmbH and distributed in the USA by Marz North America, Inc. The medication comes in a single-dose vial, containing 50 units of the drug. The packaging includes warnings that dosing units of botulinum toxins are not interchangeable between commercial products and that the medication should be kept out of the reach and sight of children. The unused portion should be discarded, and the medication must be reconstituted with preservative-free 0.9% Sodium Chloride Injection, USP. The reconstituted medication should be stored in a refrigerator at 2 to 8 degrees Celsius for up to 24 hours.*

PRINCIPAL DISPLAY PANEL - 50 units/vial Carton - Physician Sample - xeomin 14

PRINCIPAL DISPLAY PANEL - 50 units/vial Carton - Physician Sample - xeomin 14

This is a description for a physician sample of a drug called incobotulinumtoxinA provided in a single-dose vial for intramuscular use. The vial has a dosage of 100 units and contains human albumin and naert. The enclosed medication guide should be dispensed to each patient for use. The product is manufactured by MERZ AESTHETICSĀ®. A warning is given that dosing units of botulinum toxins are not interchangeable between commercial products.*

xeomin 15

xeomin 15

This is a description of a medication called incobotulinumtoxinA. This medication comes in a 50-unit vial and is intended for intramuscular use only. It is essential to discard any unused portions as usual dosage depends on patient's health and medical condition. There is a medication guide enclosed in the package to be dispensed to each patient. The product contains Clostridium Botulinum Neurotoxin Type A along with human albumin and sucrose. The medication is manufactured in Germany, and it is distributed in the United States by Merz North America. The product should be kept in a refrigerator within the temperature range of 2 to 8 degrees Celsius. The author emphasizes that the dosing units of botulinum toxin are not interchangeable between commercial products, so it's essential to follow the prescribing physician's recommendations.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.